Who
A. Rachel Leheny
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, CalciMedica; Director, Anthera Pharmaceuticals.
In numbers
- Trades disclosed
- 67
- Buys
- 18
- Sells
- 0
- Bought
- $914K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 4 Mar 2010
- Last trade
- 24 Sep 2026
- Last filed
- 28 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Sep 2026filed 28 Sep 2026 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —360,000 at $0.00 | filing |
| 24 Sep 2026filed 28 Sep 2026 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —360,000 at $0.00 | filing |
| 19 Aug 2026filed 21 Aug 2026 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —186,729 at $0.00 | filing |
| 19 Aug 2026filed 21 Aug 2026 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —186,729 at $0.00 | filing |
| 19 Aug 2026filed 21 Aug 2026 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —186,729 at $0.00 | filing |
| 19 Aug 2026filed 21 Aug 2026 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —186,729 at $0.00 | filing |
| 25 Jun 2026filed 29 Jun 2026 | CALC CalciMedicaBiotechnology | SEC FORM 4 Code A | $150K186,729 at $0.8033 | filing |
| 25 Jun 2026filed 29 Jun 2026 | CALC CalciMedicaBiotechnology | SEC FORM 4 Code A | $149K186,729 at $0.80 | filing |
| 21 Jul 2025filed 21 Jul 2025 | CALC CalciMedicaBiotechnology | SEC FORM 4 Bought | $3,4001,000 at $3.40 | filing |
| 14 Jul 2025filed 15 Jul 2025 | CALC CalciMedicaBiotechnology | SEC FORM 4 Bought | $6,1752,500 at $2.47 | filing |
| 24 Jun 2025filed 26 Jun 2025 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —77,625 at $0.00 | filing |
| 23 Apr 2025filed 25 Apr 2025 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —285,000 at $0.00 | filing |
| 5 Apr 2025filed 7 Apr 2026 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —148,482 at $0.00 | filing |
| 5 Apr 2025filed 7 Apr 2026 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —148,482 at $0.00 | filing |
| 1 Nov 2024filed 1 Nov 2024 | CALC CalciMedicaBiotechnology | SEC FORM 4 Bought | $75K20,000 at $3.75 | filing |
| 27 Aug 2024filed 28 Aug 2024 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —115,000 at $0.00 | filing |
| 27 Aug 2024filed 27 Aug 2024 | CALC CalciMedicaBiotechnology | SEC FORM 4 Bought | $4,1901,000 at $4.19 | filing |
| 28 Mar 2024filed 22 Apr 2024 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | —115,000 at $0.00 | filing |
| 23 Jan 2024filed 25 Jan 2024 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | $5,92145,543 at $0.13 | filing |
| 23 Jan 2024filed 25 Jan 2024 | CALC CalciMedicaoption or derivative · Biotechnology | SEC FORM 4 Code A | $5,92145,543 at $0.13 | filing |
News
No headline names them, or the companies they trade most, lately.